Chemically modified cell-penetrating peptides for the delivery of nucleic acids

Short nucleic acids targeting biologically important RNAs and plasmids have been shown to be promising future therapeutics; however, their hydrophilic nature greatly limits their utility in clinics and therefore efficient delivery vectors are greatly needed. Cell-penetrating peptides (CPPs) are relatively short amphipathic and/or cationic peptides that are able to transport various biologically active molecules inside mammalian cells, both in vitro and in vivo, in a seemingly non-toxic fashion. Although CPPs have proved to be appealing drug delivery vehicles, their major limitation in nucleic acid delivery is that most of the internalized peptide-cargo is entrapped in endosomal compartments following endocytosis and the bioavailability is therefore severely reduced. Several groups are working towards overcoming this obstacle and this review highlights the evidence that by introducing chemical modification in CPPs, the bioavailability of delivered nucleic acids increases significantly.

[1]  V. Ambros microRNAs Tiny Regulators with Great Potential , 2001, Cell.

[2]  Z. Dominski,et al.  Restoration of correct splicing in thalassemic pre-mRNA by antisense oligonucleotides. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[3]  Shu Wang,et al.  An endosomolytic Tat peptide produced by incorporation of histidine and cysteine residues as a nonviral vector for DNA transfection. , 2008, Biomaterials.

[4]  S. Crooke Progress in antisense technology. , 2004, Annual review of medicine.

[5]  John Archdeacon,et al.  A non-covalent peptide-based carrier for in vivo delivery of DNA mimics , 2007, Nucleic acids research.

[6]  L. Greene,et al.  Highly Efficient Small Interfering RNA Delivery to Primary Mammalian Neurons Induces MicroRNA-Like Effects before mRNA Degradation , 2004, The Journal of Neuroscience.

[7]  M. Morris,et al.  Insight into the mechanism of the peptide-based gene delivery system MPG: implications for delivery of siRNA into mammalian cells. , 2003, Nucleic acids research.

[8]  M. Eccles,et al.  Conjugate for efficient delivery of short interfering RNA (siRNA) into mammalian cells , 2004, FEBS letters.

[9]  D. A. Stein,et al.  Cell-penetrating peptide-morpholino conjugates alter pre-mRNA splicing of DMD (Duchenne muscular dystrophy) and inhibit murine coronavirus replication in vivo. , 2007, Biochemical Society transactions.

[10]  R. L. Juliano,et al.  Conjugates of Antisense Oligonucleotides with the Tat and Antennapedia Cell-Penetrating Peptides: Effects on Cellular Uptake, Binding to Target Sequences, and Biologic Actions , 2004, Pharmaceutical Research.

[11]  E. Giralt,et al.  Mechanistic aspects of CPP-mediated intracellular drug delivery: relevance of CPP self-assembly. , 2006, Biochimica et biophysica acta.

[12]  B. Davidson,et al.  Transvascular delivery of small interfering RNA to the central nervous system , 2007, Nature.

[13]  H. Merkle,et al.  Biophysical and biological studies of end-group-modified derivatives of Pep-1. , 2005, Biochemistry.

[14]  May C Morris,et al.  A non-covalent peptide-based strategy for protein and peptide nucleic acid transduction. , 2006, Biochimica et biophysica acta.

[15]  R. Brasseur,et al.  A new potent secondary amphipathic cell-penetrating peptide for siRNA delivery into mammalian cells. , 2009, Molecular therapy : the journal of the American Society of Gene Therapy.

[16]  Priscille Brodin,et al.  A Truncated HIV-1 Tat Protein Basic Domain Rapidly Translocates through the Plasma Membrane and Accumulates in the Cell Nucleus* , 1997, The Journal of Biological Chemistry.

[17]  Johan T den Dunnen,et al.  Local dystrophin restoration with antisense oligonucleotide PRO051. , 2007, The New England journal of medicine.

[18]  M. Wood,et al.  Effective exon skipping and restoration of dystrophin expression by peptide nucleic acid antisense oligonucleotides in mdx mice. , 2008, Molecular therapy : the journal of the American Society of Gene Therapy.

[19]  T. Rana,et al.  Visualizing a correlation between siRNA localization, cellular uptake, and RNAi in living cells. , 2004, Chemistry & biology.

[20]  B. Lebleu,et al.  Structural requirements for cellular uptake and antisense activity of peptide nucleic acids conjugated with various peptides. , 2006, Biochemistry.

[21]  E. Giralt,et al.  Differentiation Restricted Endocytosis of Cell Penetrating Peptides in MDCK Cells Corresponds with Activities of Rho-GTPases , 2007, Pharmaceutical Research.

[22]  T. Ohtsuki,et al.  Cellular siRNA delivery mediated by a cell-permeant RNA-binding protein and photoinduced RNA interference. , 2008, Bioconjugate chemistry.

[23]  A. Prochiantz,et al.  The third helix of the Antennapedia homeodomain translocates through biological membranes. , 1994, The Journal of biological chemistry.

[24]  K. Zatloukal,et al.  Nonviral gene transfer into fetal mouse livers (a comparison between the cationic polymer PEI and naked DNA) , 2003, Gene Therapy.

[25]  T. Hökfelt,et al.  Cell penetrating PNA constructs regulate galanin receptor levels and modify pain transmission in vivo , 1998, Nature Biotechnology.

[26]  H. Moulton,et al.  Cell-penetrating peptide-conjugated antisense oligonucleotides restore systemic muscle and cardiac dystrophin expression and function , 2008, Human molecular genetics.

[27]  Y. Jiang,et al.  Cellular delivery of a double-stranded oligonucleotide NFκB decoy by hybridization to complementary PNA linked to a cell-penetrating peptide , 2004, Gene Therapy.

[28]  Gunnar P. H. Dietz,et al.  Delivery of bioactive molecules into the cell: the Trojan horse approach , 2004, Molecular and Cellular Neuroscience.

[29]  P. Lundin,et al.  A stearylated CPP for delivery of splice correcting oligonucleotides using a non-covalent co-incubation strategy. , 2009, Journal of controlled release : official journal of the Controlled Release Society.

[30]  T. Bártfai,et al.  Evaluation of transportan 10 in PEI mediated plasmid delivery assay. , 2005, Journal of controlled release : official journal of the Controlled Release Society.

[31]  Ü. Langel,et al.  Induction of splice correction by cell‐penetrating peptide nucleic acids , 2006, The journal of gene medicine.

[32]  H Akita,et al.  Octaarginine-modified multifunctional envelope-type nanoparticles for gene delivery , 2007, Gene Therapy.

[33]  G. Divita,et al.  First step of the cell‐penetrating peptide mechanism involves Rac1 GTPase‐dependent actin‐network remodelling , 2007, Biology of the cell.

[34]  G. Nabel,et al.  Regulation of gene expression with double-stranded phosphorothioate oligonucleotides. , 1990, Science.

[35]  Ű. Langel,et al.  TP10, a delivery vector for decoy oligonucleotides targeting the Myc protein. , 2005, Journal of controlled release : official journal of the Controlled Release Society.

[36]  B. Lebleu,et al.  Cellular Uptake of Unconjugated TAT Peptide Involves Clathrin-dependent Endocytosis and Heparan Sulfate Receptors* , 2005, Journal of Biological Chemistry.

[37]  M. Pooga,et al.  Cell penetration by transportan. , 1998, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[38]  K. Pattabiraman,et al.  The design, synthesis, and evaluation of molecules that enable or enhance cellular uptake: peptoid molecular transporters. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[39]  A. Prochiantz,et al.  Downregulation of amyloid precursor protein inhibits neurite outgrowth in vitro , 1995, The Journal of cell biology.

[40]  Xiang Gao,et al.  Nonviral gene delivery: What we know and what is next , 2007, The AAPS Journal.

[41]  L. Tönges,et al.  Stearylated octaarginine and artificial virus-like particles for transfection of siRNA into primary rat neurons. , 2006, RNA.

[42]  Simon W. Jones,et al.  Lung delivery studies using siRNA conjugated to TAT(48-60) and penetratin reveal peptide induced reduction in gene expression and induction of innate immunity. , 2007, Bioconjugate chemistry.

[43]  Rainer Fischer,et al.  A Comprehensive Model for the Cellular Uptake of Cationic Cell‐penetrating Peptides , 2007, Traffic.

[44]  P. Lundin,et al.  Distinct uptake routes of cell-penetrating peptide conjugates. , 2008, Bioconjugate chemistry.

[45]  R. Kole,et al.  Up-regulation of luciferase gene expression with antisense oligonucleotides: implications and applications in functional assay development. , 1998, Biochemistry.

[46]  M. Pooga,et al.  The membrane repair response masks membrane disturbances caused by cell‐penetrating peptide uptake , 2009, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[47]  P. Nielsen,et al.  Improved cellular activity of antisense peptide nucleic acids by conjugation to a cationic peptide-lipid (CatLip) domain. , 2008, Bioconjugate chemistry.

[48]  P. Iversen,et al.  Effective rescue of dystrophin improves cardiac function in dystrophin-deficient mice by a modified morpholino oligomer , 2008, Proceedings of the National Academy of Sciences.

[49]  A. Fire,et al.  Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans , 1998, Nature.

[50]  Ü. Langel,et al.  Delivery of short interfering RNA using endosomolytic cell‐penetrating peptides , 2007, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[51]  B. Lebleu,et al.  Efficient splicing correction by PNA conjugation to an R6-Penetratin delivery peptide , 2007, Nucleic acids research.

[52]  L. Bagatolli,et al.  Energy-independent translocation of cell-penetrating peptides occurs without formation of pores. A biophysical study with pep-1 , 2007, Molecular membrane biology.

[53]  Ü. Langel,et al.  A Novel Cell-penetrating Peptide, M918, for Efficient Delivery of Proteins and Peptide Nucleic Acids. , 2007, Molecular therapy : the journal of the American Society of Gene Therapy.

[54]  H Harashima,et al.  Mechanism of improved gene transfer by the N-terminal stearylation of octaarginine: enhanced cellular association by hydrophobic core formation , 2004, Gene Therapy.

[55]  P. Iversen,et al.  Antisense oligonucleotide-induced exon skipping restores dystrophin expression in vitro in a canine model of DMD , 2006, Gene Therapy.

[56]  P. Iversen,et al.  HIV Tat peptide enhances cellular delivery of antisense morpholino oligomers. , 2003, Antisense & nucleic acid drug development.

[57]  B. Lebleu,et al.  Improved cell-penetrating peptide–PNA conjugates for splicing redirection in HeLa cells and exon skipping in mdx mouse muscle , 2008, Nucleic acids research.

[58]  J. Gariépy,et al.  Cell-surface proteoglycans as molecular portals for cationic peptide and polymer entry into cells. , 2007, Biochemical Society transactions.

[59]  E. Dupont,et al.  Cell‐surface thiols affect cell entry of disulfide‐conjugated peptides , 2009, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[60]  P. Nielsen,et al.  Enhanced delivery of cell-penetrating peptide–peptide nucleic acid conjugates by endosomal disruption , 2006, Nature Protocols.

[61]  E. Wagner,et al.  Simple modifications of branched PEI lead to highly efficient siRNA carriers with low toxicity. , 2008, Bioconjugate chemistry.

[62]  S. Futaki,et al.  Efficient short interference RNA delivery to tumor cells using a combination of octaarginine, GALA and tumor-specific, cleavable polyethylene glycol system. , 2009, Biological & pharmaceutical bulletin.

[63]  Simon W. Jones,et al.  RNA targeting with peptide conjugates of oligonucleotides, siRNA and PNA. , 2007, Blood cells, molecules & diseases.

[64]  H Harashima,et al.  Stearylated arginine-rich peptides: a new class of transfection systems. , 2001, Bioconjugate chemistry.

[65]  Shiroh Futaki,et al.  Octaarginine-modified multifunctional envelope-type nano device for siRNA. , 2007, Journal of controlled release : official journal of the Controlled Release Society.

[66]  I. Khalil,et al.  Enhanced gene expression by a novel stearylated INF7 peptide derivative through fusion independent endosomal escape. , 2009, Journal of controlled release : official journal of the Controlled Release Society.

[67]  S. W. Kim,et al.  Cholesteryl oligoarginine delivering vascular endothelial growth factor siRNA effectively inhibits tumor growth in colon adenocarcinoma. , 2006, Molecular therapy : the journal of the American Society of Gene Therapy.

[68]  G. Divita,et al.  Modulation of the typical multidrug resistance phenotype by targeting the MED-1 region of human MDR1 promoter , 2000, Gene Therapy.